March 1978

Multicenter Comparison of Naproxen and Indomethacin in Rheumatoid Arthritis

Author Affiliations

From the University of California School of Medicine, Davis (Dr Castles); Scripps Clinic and Research Foundation, La Jolla, Calif (Drs Moore and Vaughan); Tufts University School of Medicine and St Elizabeth's Hospital, Boston (Dr Bolzan); University of Florida School of Medicine, Gainesville (Drs Lee and Caldwell); Baylor College of Medicine (Dr Sharp) and Houston VA Hospital, Houston (Dr Lidsky); Temple University School of Medicine and Albert Einstein Medical Center, Philadelphia (Dr Ehrlich); and Palo Alto Medical Clinic and Stanford University School of Medicine, Palo Alto, Calif (Dr Kaye).

Arch Intern Med. 1978;138(3):362-366. doi:10.1001/archinte.1978.03630270016011

In a double-blind, crossover study, naproxen, 250 mg twice a day, naproxen, 500 mg taken at bedtime, and indomethacin, 25 mg four times a day, were compared in 132 patients with rheumatoid arthritis; six centers participated in the study. Objective indices of arthritis activity, such as number of clinically active joints, walking time, and duration of morning stiffness, were nearly identical for the three treatment regimens. Of particular interest was the observation that efficacy of a single daily dose of naproxen was comparable to that of the twice-daily dosage. Naproxen was better tolerated than indomethacin, as shown by a statistically significant difference in the incidence of CNS complaints.

(Arch Intern Med 138:362-366, 1978)